The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Abstract
We provide an overview on soft-tissue extramedullary plasmacytomas (EMPs) in multiple myeloma (MM). We reviewed the incidence of EMPs in MM, myeloma bone marrow homing, possible mechanisms of extramedullary spread, and prognosis and response to therapy. The incidence of EMPs is 7% to 18% at MM diagnosis and up to 20% at relapse. The current notion that EMPs are more frequent after treatment with novel agents remains to be proven, especially considering that different patterns of disease recurrence can emerge as patients live longer in the era of novel drugs. Bone marrow genetic abnormalities are not associated with extramedullary spread per se, which also suggests that microenvironmental interactions are key. Possible mechanisms of extramedullary spread include decreased adhesion molecule expression and downregulation of chemokine receptors. EMPs usually show plasmablastic morphology with negative CD56 expression. High-dose therapy with autologous stem-cell transplantation (ASCT) can overcome the negative prognostic impact of extramedullary disease in younger selected patients. EMPs do not typically respond to thalidomide alone, but in contrast, responses to bortezomib have been reported. The incidence of EMPs in patients with MM is high and is associated with poor outcome in patients treated conventionally. A potential first-line treatment option seems to be a bortezomib-containing regimen followed by ASCT, whenever possible. Experimental studies on the mechanisms of myeloma cell adhesion, myeloma growth at extramedullary sites, and drug sensitivity are priorities for this area of continuing therapeutic challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Inayat, M. S., Damodaran, C., Mohiuddin, M., Elford, H. L., Gallicchio, V. S., & Ahmed, M. M. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.5.174 · Cited by 100
RetractedA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Bone marrow angiogenesis and progression in multiple myeloma
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., & Dammacco, F. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08304.x · Cited by 630
Monoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Bartel, T. B., Haessler, J., Brown, T. L. Y., Shaughnessy, J. D., van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213280 · Cited by 518
Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 487
Dimopoulos, M., Terpos, E., Comenzo, R. L., Tosi, P., Beksac, M., Sezer, O., Siegel, D., Lokhorst, H., Kumar, S., Rajkumar, S. V., et al. (2009) · Leukemia · doi:10.1038/leu.2009.89 · Cited by 482
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186668 · Cited by 428
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., & Kuehl, W. M. (2010) · Blood · doi:10.1182/blood-2009-09-243535 · Cited by 288
Nakayama, T., Hieshima, K., Izawa, D., Tatsumi, Y., Kanamaru, A., & Yoshie, O. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1136 · Cited by 256
Yaccoby, S., Barlogie, B., & Epstein, J. (1998) · Blood · doi:10.1182/blood.v92.8.2908 · Cited by 255
Nowakowski, G. S., Witzig, T. E., Dingli, D., Tracz, M. J., Gertz, M. A., Lacy, M. Q., Lust, J. A., Dispenzieri, A., Greipp, P. R., Kyle, R. A., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1858 · Cited by 245
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242
Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development
Vlodavsky, I., Goldshmidt, O., Zcharia, E., Atzmon, R., Rangini-Guatta, Z., Elkin, M., Peretz, T., & Friedmann, Y. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0420 · Cited by 226
III. On a new substance occurring in the urine of a patient with mollities ossium
Jones, H. B. (1848) · Philosophical Transactions of the Royal Society of London · doi:10.1098/rstl.1848.0003 · Cited by 218
Bladé, J., Kyle, R. A., & Greipp, P. R. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.5191061.x · Cited by 201
Self-citationBladé, J., Lust, J. A., & Kyle, R. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2398 · Cited by 198
Self-citationRasmussen, T., Kuehl, M., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2005) · Blood · doi:10.1182/blood-2004-03-0833 · Cited by 163
Extraskeletal spread in multiple plasma cell myeloma:A review of 57 autopsied cases
Pasmantier, M. W., & Azar, H. A. (1969) · Cancer · doi:10.1002/1097-0142(196901)23:1<167::aid-cncr2820230122>3.0.co;2-0 · Cited by 162
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Urashima, M., Chen, B. P., Chen, S., Pinkus, G. S., Bronson, R. T., Dedera, D. A., Hoshi, Y., Teoh, G., Ogata, A., Treon, S. P., et al. (1997) · Blood · doi:10.1182/blood.v90.2.754 · Cited by 159
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 155
Extramedullary lesions in multiple myeloma; review of literature and pathologic studies.
Dw, H., BENNETT, W. A., & Fj, H. (1952) · PubMed · Cited by 154
Mast cell–derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors
Nakayama, T., Yao, L., & Tosato, G. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22089 · Cited by 151
Central nervous system myelomatosis: review of the literature
Nieuwenhuizen, L., & Biesma, D. H. (2008) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00956.x · Cited by 147
Pilarski, L. M., Hipperson, G., Seeberger, K. L., et al. (2000) · Blood · doi:10.1182/blood.v95.3.1056.003k26_1056_1065 · Cited by 138
Mitsiades, C. S., McMillin, D. W., Klippel, S., Hideshima, T., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.007 · Cited by 138
Yata, K., & Yaccoby, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403513 · Cited by 135
Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol, L., Cibeira, M. T., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Segarra, M., Cid, M. C., Filella, X., & Montserrat, E. (2004) · PubMed · Cited by 134
Self-citationHeparanase promotes the spontaneous metastasis of myeloma cells to bone
Yang, Y., MacLeod, V., Bendre, M. S., Huang, Y., Theus, A. M., Miao, H., Kussie, P. H., Yaccoby, S., Epstein, J., Suva, L. J., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2141 · Cited by 134
Bortezomib: an effective agent in extramedullary disease in multiple myeloma
Rosiñol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O., Bladé, J., & Montserrat, E. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2462.x · Cited by 131
Self-citationRichardson, P. G. G., Barlogie, B., Berenson, J. R., Singhal, S., Jagannath, S., Irwin, D. H., Rajkumar, S. V., Hideshima, T., Xiao, H., Esseltine, D. L., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0691 · Cited by 128
A clinically relevant SCID-hu in vivo model of human multiple myeloma
Tassone, P., Neri, P. E., Carrasco, D. R., Burger, R., Goldmacher, V. S., Fram, R. J., Munshi, V. N., Shammas, M. A., Catley, L. P., Jacob, G. S., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0373 · Cited by 115
The impact of extramedullary disease at presentation on the outcome of myeloma
Wu, P., Davies, F. E., Boyd, K. D., Thomas, K., Dines, S., Saso, R. M., Potter, M. N., Ethell, M. E., Shaw, B. E., & Morgan, G. J. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802657751 · Cited by 115
Witzig, T. E., Gertz, M. A., Lust, J., Kyle, R. A., Wm, O., & Greipp, P. (1996) · Blood · doi:10.1182/blood.v88.5.1780.1780 · Cited by 115
Extravasation and homing mechanisms in multiple myeloma
Broek, I. V., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9108-4 · Cited by 113
Multiple Myeloma Invasion of the Central Nervous System
Schluterman, K. O., Fassas, A., Hemert, R. L. V., & Harik, S. I. (2004) · Archives of Neurology · doi:10.1001/archneur.61.9.1423 · Cited by 108
Multiple Myeloma: Lesions of the Extra-osseous Hematopoietic System
Churg, J., & Gordon, A. J. (1950) · American Journal of Clinical Pathology · doi:10.1093/ajcp/20.10.934 · Cited by 105
Multiple Myeloma in Patients Younger Than 30 Years
Bladé, J. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120125014 · Cited by 103
Self-citationMitsiades, C. S., Mitsiades, N., Bronson, R. T., Chauhan, D., Munshi, N. C., Treon, S. P., Maxwell, C. A., Pilarski, L. M., Hideshima, T., Hoffman, R. M., et al. (2003) · PubMed · Cited by 102
Monoclonal Gammopathy of Undetermined Significance
Bladé, J. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp052790 · Cited by 101
Self-citationPérez‐Simón, J. A., Sureda, A., Fernández‐Avilés, F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404085 · Cited by 91
Alegre, A. M., Granda, A., Martínez Chamorro, C., Díaz Mediavilla, J., Martínez, R., García Laraña, J., Lahuerta, J. J., Sureda, A. M., Bladé, J., de la Rubia, J., et al. (2002) · PubMed · doi:10.5281/zenodo.11276358 · Cited by 89
Self-citationDawson, M. A., Patil, S., & Spencer, A. G. (2007) · Haematologica · doi:10.3324/haematol.10297 · Cited by 87
Broek, I. V., Broek, I. V., Leleu, X. P., Schots, R., Facon, T., Vanderkerken, K., Camp, B. V., & Riet, I. V. (2006) · PubMed · Cited by 87
Bone marrow angiogenesis and progression in multiple myeloma.
Ria, R., Reale, A., Luisi, A. D., Ferrucci, A., Moschetta, M., & Vacca, A. (2011) · PubMed · Cited by 83
Fassas, A., Ward, S. M., Muwalla, F., Hemert, R. L. V., Schluterman, K. O., Harik, S. I., & Tricot, G. J. K. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001597964 · Cited by 82
Zeiser, R., Deschler-Baier, B., Bertz, H., Finke, J., & Engelhardt, M. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704713 · Cited by 81
Mouse plasmacytoma: an experimental model of human multiple myeloma.
Gadó, K., Silva, S., Pálóczi, K., Domján, G., & Falus, A. (2001) · PubMed · Cited by 75
Lenhoff, S., Hjorth, M., Turesson, I., Westin, J., Gimsing, P., Wislöff, F., Ahlberg, L., Carlson, K. E., Christiansen, I., Dahl, I. M. S., et al. (2006) · PubMed · Cited by 72
Menu, E., Asosingh, K., Indraccolo, S., Raeve, H. D., Riet, I. V., Valckenborgh, E. V., Broek, I. V., de Broek, I. V., Fujii, N., Tamamura, H., et al. (2006) · PubMed · Cited by 70
Hedvat, C. V., Comenzo, R. L., Teruya‐Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., Zhang, Y., Kalakonda, N., & Nimer, S. D. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04481.x · Cited by 69
Patriarca, F. F., Prosdocimo, S., Tomadini, V., Vasciaveo, A., Bruno, B., & Fanin, R. (2005) · PubMed · Cited by 65
Avigdor, A., Raanani, P., Levi, I., Hardan, I., & Ben‐Bassat, I. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099330 · Cited by 59
Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential
Tohami, T., Drucker, L., Shapiro, H., Radnay, J., & Lishner, M. (2007) · The FASEB Journal · doi:10.1096/fj.06-6610com · Cited by 55
Asosingh, K., Günthert, U., Raeve, H. D., et al. (2001) · PubMed · doi:10.5451/unibas-ep6480 · Cited by 54
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma
López‐Anglada, L., Gutierrez, N. C., Garcı́a, J. L., Mateos, M., Flores, T., & Miguel, J. F. S. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01399.x · Cited by 54
Minnema, M. C., van de Donk, N. W. C. J., Zweegman, S., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705982 · Cited by 53
Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse
Vanderkerken, K., Greef, C. D., Asosingh, K., Arteta, B., Veerman, M. D., Broek, I. V., Riet, I. V., Kobayashi, M., Smedsrød, B. H., & Camp, B. V. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1024 · Cited by 52
Katodritou, E., Gastari, V., Verrou, E., Hadjiaggelidou, C., Varthaliti, M., Georgiadou, S., Laschos, K., Xirou, P., Yiannaki, E. E., Constantinou, N., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.036 · Cited by 46
Rosiñol, L., Cibeira, M. T., Martínez‐López, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.130.130 · Cited by 45
Self-citationThalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients
Oliveira, A. M., Maria, D. A., Metzger, M., Linardi, C. C. G., Giorgi, R. R., Moura, F., Martınez, G., Bydlowski, S. P., & Novak, E. M. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.09.018 · Cited by 43
Biagi, J., Mileshkin, L., Grigg, A., Westerman, D., & Prince, H. M. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703292 · Cited by 42
Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma
Černý, J., Fadare, O., Hutchinson, L., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01087.x · Cited by 41
Chamberlain, M. C., & Glantz, M. (2008) · Cancer · doi:10.1002/cncr.23330 · Cited by 41
Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis
Dimopoulos, M. A., Pouli, A. G., Anagnostopoulos, A., Repoussis, P., Symeonidis, A. S., Terpos, E., Delimbasi, S., Tsolakis, F., Economopoulos, T., & Zervas, C. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600647723 · Cited by 38
Molecular Pathogenesis of Multiple Myeloma
Tonon, G. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.004 · Cited by 36
Rosenblum, M. D., Bredeson, C., Chang, C.-C., & Rizzo, J. D. (2003) · American Journal of Hematology · doi:10.1002/ajh.10296 · Cited by 35
Kumar, S. K., Flinn, I. W., Richardson, P. G. G., Hari, P., Callander, N. S., Noga, S. J., Stewart, A. K., Glass, J., Rifkin, R. M., Wolf, J. L., et al. (2010) · Blood · doi:10.1182/blood.v116.21.621.621 · Cited by 34
Paubelle, É., Coppo, P., Garderet, L., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403855 · Cited by 32
Mitsiades, C. S., Anderson, K. C., & Carrasco, D. R. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.003 · Cited by 29
Extensive soft‐tissue involvement by plasmablastic myeloma arising from displaced humeral fractures
de Larrea, C. F., Rosiñol, L., Cibeira, M. T., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01504.x · Cited by 27
Self-citationLack of response to thalidomide in plasmacytomas
Myers, B., Grimley, C., Crouch, D. J. M., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.0115_1cr-6.x · Cited by 26
Blimp1 is limiting for transformation in a mouse plasmacytoma model
D’Costa, K., Emslie, D., Metcalf, D., Smyth, G. K., Karnowski, A., Kallies, A., Nutt, S. L., & Corcoran, L. M. (2009) · Blood · doi:10.1182/blood-2008-08-172866 · Cited by 22
Anagnostopoulos, A., Gika, D., Hamilos, G., Zervas, K., Zomas, A., Pouli, A. G., Zorzou, M. P., Kastritis, E., Anagnostopoulos, N. I., Tassidou, A., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001733772 · Cited by 18
Cited by
Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Extramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
Self-citationNew criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Oliva, S., D'Agostino, M., Boccadoro, M., & Larocca, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00001 · Cited by 291
Rosiñol, L., Beksac, M., Zamagni, E., Van de Donk, N. W. C. J., Anderson, K. C., Badros, A., Caers, J., Cavo, M., Dimopoulos, M., Dispenzieri, A., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17338 · Cited by 179
Self-citation
Metadata
- Authors
- Bladé, J., Fernández de Larrea, C., Rosiñol, L., Cibeira, M. T., Jiménez, R., & Powles, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-10-01
- Volume
- 29
- Issue
- 28
- Pages
- 3805-3812
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1988755171
- Cited by
- 387
- References
- 84
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.